Ampio Pharmaceuticals 8-K Indicates FDA Said In Response Letter That It Does Not Consider AP-0003-C Trial To Be Adequate And Well-Controlled Clinical Trial And Recommended Co. Performs Randomized Trial With Concurrent Trial; Shares Down 54.7% After Hours